As part of a broad development programme, the initial clinical trial will measure the extent that CeNeS' novel CEE 03-310 drug reduces problem drinkers' craving for alcohol and its consumption.
Alcohol abuse is a major social problem.
In Britain alone, recent data shows that as many as one in twenty adults has a drink problem. Current treatments for alcohol abuse are limited, and none directly address the craving for alcohol. About CeNeS CeNeS Pharmaceuticals is focused on developing drugs for CNS disorders and pain control and the development of controlled release drug delivery products in a range of therapeutic areas. All rights reserved. Reproduction or copying of images prohibited.